
    
      Participants with MRD-positive B cell acute lymphoblastic leukemia can participate if all
      eligibility criteria are met. Tests required to determine eligibility include disease
      assessments, a physical exam, Electrocardiograph, CT/MRI , and blood draws. Participants
      receive chemotherapy prior to the infusion of CD19/CD22 CAR+ T cells. After the infusion,
      participants will be followed for side effects and effect of CD19/CD22 CAR+ T cells. Study
      procedures may be performed while hospitalized.
    
  